Runner Up: Incidence of Cutaneous Adverse Events with PI3K-Akt-mTOR Pathway Inhibitors: A Systematic Review and Network Meta-Analysis. J of Skin [Internet]. 2022 May 6 [cited 2026 Apr. 22];6(3):s39. Available from: https://skin.dermsquared.com/skin/article/view/1580